Congratulations to the 2025 Award Recipients

Mr. Wright Lassiter III is the 2025 ABHP Health-system Leadership Award Recipient

Dr. Dawn Moore is the ABHP 2025 Wendell T. Hill Award Recipient

Dr. Anthony Scott is the 2025 ASHP-ABHP Joint Leadership Award Recipient

Audrea Juny Simpson is the 2025 ABHP Industry Relations Award Recipient

Tony Jackson is the 2025 Presdent's Award Recipient

Britnee Innocent is the 2025 Student Achievement Award Recipient

Desiree Dennis is the 2025 Student Achievement Award Recipient

Lauren Wells is the 2025 Student Achievement Award Recipient

AFRICAN AMERICAN PHARMACY HISTORY - CALL FOR CONTRIBUTORS

The Association of Black Health-system Pharmacists (ABHP) invites volunteer contributors to help document, preserve, and amplify the rich and often underrepresented history of Black pharmacists and Black pharmacy practice in the United States and beyond. For more information, click the button below.

MORE
woman inside laboratory

ABHP ADVOCACY TO PROTECT 340B DRUG PRICING PROGRAM

The Association of Black Health-system Pharmacists (ABHP) believes: All Americans need access to prescription medications and pharmacist-provided patient care services to help them optimize therapeutic outcomes and reduce the risk of adverse events from medication therapy. The 340B program is essential to covered entities’ ability to advance its direct patient care goals and provide healthcare services to vulnerable patients and communities, including access to medications for the uninsured and underserved patients. Pharmacists are a highly trained and valuable resource. Many are certified and have training in specialty areas such as cardiovascular care, diabetes, and asthma, yet they are currently underutilized. The 340B program allows for strategies to maximize equity and safety of drug distribution and collaborative disease management with physicians while providing patients with access to the full benefit of pharmacist-provided patient care services to achieve better health care. Any efforts to scale back, significantly reduce the benefits of, or expand the regulatory burden of the 340B program, including proposals to dramatically expand reporting requirements on certain 340B hospitals and impose a moratorium on new entrants into the program, are areas we oppose. 

MORE
woman inside laboratory

Subscribe

Sign up to our newsletter and stay up to date

Subscribed!

Thank you for subscribing to our newsletter.